The choice of tracer can determine who gets diagnosed and who doesn't
In the long effort to catch Alzheimer's disease before it steals what is most human, a team at the University of Pittsburgh has found that the instrument of detection may matter as much as the act of looking. By comparing two chemical tracers used to illuminate tau tangles in living brains, they discovered that a newer compound called MK6240 identifies disease markers more than twice as often as the current FDA-approved standard — a difference that, in practice, determines who receives treatment and who is turned away. The finding, published in The Lancet, arrives at a moment when new therapies are emerging and the precision of diagnosis has never carried higher stakes.
- The standard tau imaging tracer used in clinics today may be leaving hundreds of thousands of early Alzheimer's patients undetected and untreated.
- A head-to-head study of 775 participants revealed MK6240 caught tau pathology in 15% of at-risk patients versus only 6% with the current standard — 23 additional diagnoses per 100 people scanned.
- The gap grows wider in patients already showing cognitive symptoms, raising urgent questions about how many people have been wrongly excluded from clinical trials and emerging therapies.
- Scientists are now navigating a double-edged tension: a more sensitive tracer could open treatment access to those who need it, but may also flag tau changes that would never cause harm.
- MK6240 remains experimental and awaits FDA approval, but a $40 million NIH-backed initiative is pushing to standardize tau measurement before the next generation of Alzheimer's drugs reaches patients.
Researchers at the University of Pittsburgh have uncovered a quiet but consequential flaw in how Alzheimer's disease is detected: the chemical tracer a doctor chooses to illuminate tau protein tangles in the brain can determine whether a patient is diagnosed at all.
Tau tangles are not merely a footnote in Alzheimer's biology — they appear to be its most dangerous chapter. While amyloid plaques accumulate in many aging brains without causing dementia, the arrival of tau alongside amyloid seems to trigger a cascade of damage leading to memory loss and cognitive decline. Identifying tau early and accurately could mean the difference between timely treatment and years of invisible deterioration.
To test whether the choice of tracer truly matters, the Pittsburgh team scanned 775 participants twice on the same day — once with Flortaucipir, the FDA-approved standard, and once with MK6240, a newer experimental compound. The paired design was deliberate: scanning the same person at the same moment stripped away any noise from disease progression, isolating what each tracer alone could reveal.
The results were stark. In cognitively unimpaired patients who already had amyloid in their brains, MK6240 detected tau positivity in 15% of cases versus just 6% with Flortaucipir. Among those with mild cognitive impairment or dementia, the newer tracer identified substantially more cases as well. In practical terms, a patient who scans negative with the current standard might be denied access to emerging anti-amyloid therapies — while the same patient, scanned with MK6240, could qualify for treatment.
The findings raise an equally important counterquestion: does greater sensitivity mean greater accuracy, or does MK6240 sometimes flag tau changes that would never cause symptoms? That tension sits at the heart of why this research matters and why regulatory scrutiny will be essential.
The study is part of a broader NIH-funded initiative, launched in 2021 with more than $40 million, to standardize how Alzheimer's biology is measured as new therapies arrive. Flortaucipir remains the only tau tracer approved for routine clinical use. Whether MK6240 eventually joins it — and reshapes who gets diagnosed, who enrolls in trials, and who receives treatment — may be one of the most consequential diagnostic questions in neurology today.
Researchers at the University of Pittsburgh have identified a significant gap in how Alzheimer's disease is currently detected in the clinic. The problem is not with the concept of brain imaging itself, but with which chemical tracer doctors use to light up the disease's telltale signs during a scan. In a study published in The Lancet, they compared two different tracers designed to highlight tau protein tangles—the twisted fibers that accumulate in Alzheimer's brains and correlate most closely with cognitive decline. What they found matters: the choice of tracer can determine who gets diagnosed and who doesn't.
Tau is not the only hallmark of Alzheimer's disease, but it appears to be the most consequential one. Many people accumulate amyloid plaques, another signature of the disease, without ever developing dementia. But when tau tangles appear alongside those plaques, something shifts. The combination seems to unlock a cascade of damage that leads to memory loss and cognitive decline. This is why detecting tau early and precisely could reshape how doctors identify patients who truly need treatment—and spare others from expensive, burdensome procedures they may never require.
To test whether imaging tracers make a real difference, the Pittsburgh team enrolled 775 participants in a head-to-head comparison. Each person received two tau scans on the same day or within a short window: one using Flortaucipir, the standard tracer approved by the FDA, and another using MK6240, a newer compound still primarily confined to research settings. The participants also underwent amyloid imaging and cognitive testing. The paired design was deliberate. By scanning the same person at the same moment in their disease course, the researchers could isolate what the tracers themselves revealed, rather than confusing the picture with changes that might occur over weeks or months.
The results were striking. MK6240 detected tau positivity more than twice as often as Flortaucipir in people without cognitive symptoms but with amyloid in their brains—15 percent versus 6 percent. That translates to 23 additional cases identified per 100 people scanned. Among those already showing cognitive impairment, the gap widened further. MK6240 found tau involvement in 28 percent of participants compared to 16 percent with Flortaucipir, meaning 15 additional mild cognitive impairment cases and 21 additional dementia cases per 100 people would be detected with the newer tracer.
These numbers carry real weight in clinical practice. A patient who tests negative on a Flortaucipir scan might be told they do not yet have evidence of tau pathology and may not be eligible for emerging anti-amyloid therapies. The same patient scanned with MK6240 could receive a different diagnosis and access to treatment. Conversely, the newer tracer's sensitivity raises questions about specificity—whether it identifies true disease or picks up tau changes that would never cause symptoms. That tension is precisely why the research matters and why the next steps are critical.
The Pittsburgh study builds on a larger research initiative launched in 2021, when the National Institutes of Health awarded the team more than $40 million over five years to systematically compare tau tracers and standardize how Alzheimer's biology is measured across research and clinical settings. The work reflects a broader shift in neurology: as new drugs targeting amyloid and tau emerge, the ability to identify who will benefit becomes as important as the drugs themselves. Right now, Flortaucipir is the only tau tracer approved by the FDA for routine clinical use. MK6240 remains experimental. But if the Pittsburgh findings hold and regulatory approval follows, the diagnostic landscape for Alzheimer's disease could shift substantially. The question is not whether tau imaging matters—the science is clear on that. The question is which tracer will become the standard, and what that choice means for millions of people at risk.
Citações Notáveis
If we can detect tau earlier and stage it more precisely, we can make better decisions about who is truly on an Alzheimer's trajectory, which matters for clinical trials now and could shape clinical decision-making as new therapies emerge.— Tharick Pascoal, M.D., Ph.D., associate professor of psychiatry and neurology at University of Pittsburgh
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter which tracer you use if both are detecting the same protein?
Because they're not equally sensitive. MK6240 catches tau tangles earlier and in more people. If you use the less sensitive tracer, you miss cases that might benefit from treatment.
So the newer one is always better?
Not necessarily. Sensitivity and specificity are different things. A tracer that lights up more tau might be catching changes that never cause symptoms. That's why we need to understand what MK6240 is actually detecting.
How does this change what doctors do right now?
Right now, a patient might test negative on Flortaucipir and be told they're not on an Alzheimer's trajectory. With MK6240, that same patient could test positive and become eligible for new drugs. It's not a small difference.
Is MK6240 going to replace Flortaucipir?
That's the open question. It's not FDA-approved yet for routine clinical use. The Pittsburgh study makes the case for why it should be, but approval and adoption are separate processes.
What happens to people who've already been scanned with Flortaucipir?
They might need rescanning if MK6240 becomes standard. That's one of the practical complications—changing diagnostic standards mid-stream affects real patients and real decisions they've already made.